Ozempic drug found to reduce heart risk in overweight non-diabetics
A clinical trial has found that the cardiovascular benefits that the drug semaglutide affords to overweight or obese type 2 diabetics extend to those without diabetes as well. The study suggests that the drug offers a new way to reduce the potentially deadly risks associated with obesity and being…